EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Understanding genetic heterogeneity in gene-edited hematopoietic stem cell products

Hans Jiro Becker, Satoshi Yamazaki

Experimental Hematology · 2024-01 · 129 · 104133

DOI: 10.1016/j.exphem.2023.11.007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Hematology, 2024-01. Verfasst von Hans Jiro Becker und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Stem Cell Therapy, Faculty of Medicine, Tsukuba University, Tsukuba, Japan; Division of Cell Regulation, Center of Experimental Medici…. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Deutsche Forschungsgemeinschaft, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR/Cas gene editing has transformed genetic research and is poised to drive the next generation of gene therapies targeting hematopoietic stem cells (HSCs). However, the installation of the "desired" edit is most often only achieved in a minor subset of alleles. The array of cellular pathways triggered by gene editing tools produces a broad spectrum of "undesired" editing outcomes, including short insertions and deletions (indels) and chromosome rearrangements, leading to considerable genetic heterogeneity in gene-edited HSC populations. This heterogeneity may undermine the effect of the genetic intervention since only a subset of cells will carry the intended modification. Also, undesired mutations represent a potential safety concern as gene editing advances toward broader clinical use. Here, we will review the different sources of "undesired" edits and will discuss strategies for their mitigation and control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingCRISPR-Cas SystemsGenetic HeterogeneityHematopoietic Stem CellsMutation

Autor:innen und Institutionen

  • Laboratory for Stem Cell Therapy, Faculty of Medicine, Tsukuba University, Tsukuba, Japan; Division of Cell Regulation, Center of Experimental Medicine and Systems Biology, The Institute of Medical Science, The Universi…

Förderung

  • Japan Agency for Medical Research and Development
  • Deutsche Forschungsgemeinschaft
  • Japan Society for the Promotion of Science

Zitieren

APA

Becker, H. J., & Yamazaki, S. (2024). Understanding genetic heterogeneity in gene-edited hematopoietic stem cell products. Experimental Hematology, 129, 104133. https://doi.org/10.1016/j.exphem.2023.11.007

Vancouver

Becker HJ, Yamazaki S. Understanding genetic heterogeneity in gene-edited hematopoietic stem cell products. Experimental Hematology. 2024;129:104133. doi:10.1016/j.exphem.2023.11.007

BibTeX
@article{Becker2024,
  author = {Becker, Hans Jiro and Yamazaki, Satoshi},
  title = {Understanding genetic heterogeneity in gene-edited hematopoietic stem cell products},
  journal = {Experimental Hematology},
  year = {2024},
  volume = {129},
  pages = {104133},
  doi = {10.1016/j.exphem.2023.11.007}
}
Kostenlos starten →